Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes

Sharma, Shweta; Agrawal, R P; Choudhary, Maya; Jain, Shreyans; Goyal, Shekhar; Agarwal, Vivek

doi:10.1016/j.jtemb.2011.03.003

Cited by 96 publications

(68 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Again, in 10 studies, the FPG levels in the placebo arm also decreased. Large changes were noted in the placebo arms of 2 studies; in a single-blind study, 57 FPG increased from 12.6 to 13.8 mmol/L (eg, 226-248 mg/dL), and in the other study, in which 26 (13 on chromium and 13 controls) of 39 subjects had dropped out, 47 FPG decreased from 14.4 to 12.3 mmol/L (259-221 mg/dL). Striking changes in FPG were not evident in the remainder of studies, and values generally remained above treatment goals.…”

Section: Studies Measuring Hba1cmentioning

confidence: 96%

“…22 Cefalu et al (2010) 23 Chen et al (2014) 24 Crawford et al (1999) 25 Evans (1989) 26 Ghosh et al (2002) 27 Gunton et al (2005) 28 Grant and McMullen. (1982) 29 Grant et al (1997) 30 Hermann et al (1998) 31 Hermann et al (1994) 32 Jain et al (2012) 40 Lee and Reasner (1994) 41 Li et al (1992) 42 Li (1994) 43 45 Martinez et al (1985) 46 Mossop (1983) 47 Offenbacher and Pi-Sunyer (1980) 48 Offenbacher et al (1985) 49 Pasman et al (1997) 50 Pei et al (2006) 51 Rabinovitz et al (1983) 52 Rabinovitz et al (2004) 53 Racek et al (2006) 54 Riales et al (1981) 55 Singer and Geohas (2006) 56 Sharma et al (2011) 57 Sherman et al (1968) 58 Thomas and Gropper (1996) 59 Urberg and Zemel (1987) 60 …”

Section: Studies Measuring Hba1cmentioning

confidence: 99%

“…The only study of patients not taking hypoglycemic medications concurrently with the chromium supplement was the trial of Sharma et al, 57 in which 20 individuals with new-onset T2DM were given a brewer's yeast supplement (42 lg of chromium per day) for 12 weeks in a single-blind RCT using an ITT analysis in India. The mean HbA1c of 9.5% at baseline fell to 6.9%, reaching the treatment goal range after supplementation.…”

Section: Studies Measuring Hba1cmentioning

confidence: 99%

“…One study of patients who were not receiving hypoglycemic medications was of particular interest and was therefore examined in greater depth in an attempt to discover similarities that might account for the favorable responses. The Sharma et al 57 trial enrolled subjects in India with newly diagnosed T2DM. Although it was small (n ¼ 20 subjects) and its duration was only 12 weeks, it was well controlled and employed an ITT design, so that the strengths of randomization were preserved.…”

Section: Studies Measuring Fasting Plasma Glucosementioning

confidence: 99%

“…In addition to the Sharma et al 57 study, there were 2 other trials of patients who did not take hypoglycemic medications, but the analysis of study results was flawed. The Mossop, 47 trial conducted in Africa, showed decreases in FPG, but the number of dropouts was considerable (of the 39 patients at baseline, only 13 on the chromium intervention completed the study), and noncompliers and dropouts were excluded from the analysis (ie, per-protocol, not ITT).…”

Section: Studies Measuring Fasting Plasma Glucosementioning

confidence: 99%

See 4 more Smart Citations

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

2016

View full text Add to dashboard Cite

Some adults with type 2 diabetes mellitus (T2DM) believe that chromium-containing supplements will help control their disease, but the evidence is mixed. This narrative review examines the efficacy of chromium supplements for improving glycemic control as measured by decreases in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). Using systematic search criteria, 20 randomized controlled trials of chromium supplementation in T2DM patients were identified. Clinically meaningful treatment goals were defined as an FPG of 7.2 mmol/dL, a decline in HbA1c to 7%, or a decrease of 0.5% in HbA1c. In only a few randomized controlled trials did FPG (5 of 20), HbA1c (3 of 14), or both (1 of 14) reach the treatment goals with chromium supplementation. HbA1c declined by 0.5% in 5 of 14 studies. On the basis of the low strength of existing evidence, chromium supplements have limited effectiveness, and there is little rationale to recommend their use for glycemic control in patients with existing T2DM. Future meta-analyses should include only high-quality studies with similar forms of chromium and comparable inclusion/exclusion criteria to provide scientifically sound recommendations for clinicians.

show abstract

Section: Studies Measuring Hba1cmentioning

confidence: 96%

Section: Studies Measuring Hba1cmentioning

confidence: 99%

Section: Studies Measuring Hba1cmentioning

confidence: 99%

Section: Studies Measuring Fasting Plasma Glucosementioning

confidence: 99%

Section: Studies Measuring Fasting Plasma Glucosementioning

confidence: 99%

See 3 more Smart Citations

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

2016

View full text Add to dashboard Cite

show abstract

The oligoelements

Carvalho

Coelho

Acevedo

et al. 2015

Handbook of Mineral Elements in Food

View full text Add to dashboard Cite

Ameliorative effect of a nano chromium metal–organic framework on experimental diabetic chronic kidney disease

Fakharzadeh

Kalanaky²,

Argani

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Metal–Organic Frameworks (MOFs) are a new class of crystalline porous structures which can be used as a novel structure in diverse fields of medical science. Several studies have shown that chromium supplementation can be effective in amelioration of biochemical parameters of diabetes and its renal complications. Therefore, a chromium‐containing MOF (DIFc) was synthetized by nanochelating technology in the present study and then its effect on biochemical indices in diabetic rats was evaluated. Diabetes was induced by high‐fat diet consumption and streptozotocin (35 mg/kg) injection and then the treatment started 8 weeks after disease induction and continued for 8 weeks. The results showed that DIFc treatment decreased HOMA‐IR index, blood urea nitrogen, uric acid and malondialdehyde in plasma samples. This nano MOF also reduced albumin, malondialdehyde and 8‐isoprostane in urine specimen, while it increased creatinine clearance. In conclusion, DIFc MOF demonstrated promising results in the present study, indicating that it can be developed and evaluated in future investigations with the aim of designing a novel agent for management of diabetes and its renal complications.

show abstract

Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes

Cited by 96 publications

References 36 publications

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

The oligoelements

Ameliorative effect of a nano chromium metal–organic framework on experimental diabetic chronic kidney disease

Contact Info

Product

Resources

About